Company
Headquarters: Clayton, VIC, Australia
CEO: Ms. Melinda McGrath
A$514.7 Million
AUD as of July 1, 2024
US$342.8 Million
Company | Market Cap (USD) |
---|---|
Thermo Fisher Scientific | $219.88 B |
Danaher | $177.43 B |
Siemens Healthineers AG | $59.19 B |
Agilent Technologies, Inc. | $43.57 B |
Lonza Group Ltd | $41.66 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Australian Clinical Labs Limited provides pathology services. The company offers various routine pathology tests, advanced pathology, first trimester screening and non-invasive prenatal testing, chemical pathology, hematology, histopathology, immunology, serology and microbiology, functional pathology, and commercial drug and alcohol testing services. The company offers its service to private and public hospitals. Australian Clinical Labs Limited was incorporated in 2020 and is based in Clayton, Australia.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | June 30, 2023 |
Revenue TTM | A$674.0 M |
EBITDA | A$174.6 M |
Gross Profit TTM | A$566.0 M |
Profit Margin | 2.29% |
Operating Margin | 6.95% |
Quarterly Revenue Growth | -6.40% |
Australian Clinical Labs Ltd has the following listings and related stock indices.
Stock: ASX: ACL wb_incandescent